Genetics: Prostate cancer risk stratification by genotype and PSA

Nature Reviews Urology

Volumn 6, Issue 12, 2009, Pages 641-642

  Wright, Jonathan L ^a   Lin, Daniel W ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ALLELE; CANCER MORTALITY; CANCER RISK; CHROMOSOME 10; CHROMOSOME 19; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; FAMILY HISTORY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; GENOTYPE; HUMAN; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM;

GENOTYPE; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 75149134013     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2009.229     Document Type: Short Survey

References (10)

1. Palmer, L. J. & Cardon, L. R. shaking the tree: mapping complex disease genes with linkage disequilibrium. Lancet 366, 1223-1234 (2005).
2. witte, J. s. Prostate cancer genomics: towards a new understanding. Nat. Rev. Genet. 10, 77-82 (2009).
3. Loeb, S. et al. single nucleotide polymorphisms and the likelihood of prostate cancer at a given prostate specific antigen level. J. Urol. 182, 101-104 (2009).
4. Andriole, G. L. et al. Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 360, 1310-1319 (2009).
5. schroder, F. H. et al. screening and prostatecancer mortality in a randomized european study. N. Engl. J. Med. 360, 1320-1328 (2009).
6. Brown, E. Jr. Screening for prostate cancer with the prostate-specific antigen test, United States, 2002. Statistical Brief #42 (Agency for Healthcare Research and Quality, Rockville, MD, 2004).
7. Risk, M. C. & Lin, D. W. new and novel markers for prostate cancer detection. Curr. Urol. Rep. 10, 179-186 (2009).
8. Barnholtz-Sloan, J. S., Mcevoy, B., Shriver, M. D. & Rebbeck, T. R. Ancestry estimation and correction for population stratification in molecular epidemiologic association studies. Cancer Epidemiol. Biomarkers Prev. 17, 471-477 (2008).
9. Draisma, G. et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J. Natl Cancer Inst. 101, 374-383 (2009).
10. Welch, H. G. & Albertsen, P. C. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J. Natl Cancer Inst. 101, 1325-1329 (2009).